Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Solin JN"'
Autor:
Fear VS; National Centre for Asbestos Related Diseases (NCARD). Lv5 QQ Block (M503). QEII Medical Centre, The University of Western Australia, Perth, Australia.; School of Biomedical Sciences, The University of Western Australia, Perth, Australia., Tilsed C; National Centre for Asbestos Related Diseases (NCARD). Lv5 QQ Block (M503). QEII Medical Centre, The University of Western Australia, Perth, Australia.; School of Biomedical Sciences, The University of Western Australia, Perth, Australia., Chee J; National Centre for Asbestos Related Diseases (NCARD). Lv5 QQ Block (M503). QEII Medical Centre, The University of Western Australia, Perth, Australia.; School of Biomedical Sciences, The University of Western Australia, Perth, Australia., Forbes CA; National Centre for Asbestos Related Diseases (NCARD). Lv5 QQ Block (M503). QEII Medical Centre, The University of Western Australia, Perth, Australia.; School of Biomedical Sciences, The University of Western Australia, Perth, Australia., Casey T; National Centre for Asbestos Related Diseases (NCARD). Lv5 QQ Block (M503). QEII Medical Centre, The University of Western Australia, Perth, Australia.; School of Biomedical Sciences, The University of Western Australia, Perth, Australia., Solin JN; National Centre for Asbestos Related Diseases (NCARD). Lv5 QQ Block (M503). QEII Medical Centre, The University of Western Australia, Perth, Australia., Lansley SM; Centre for Respiratory Health, School of Biomedical Sciences, University of Western Australia, Perth, Australia., Lesterhuis WJ; National Centre for Asbestos Related Diseases (NCARD). Lv5 QQ Block (M503). QEII Medical Centre, The University of Western Australia, Perth, Australia.; School of Biomedical Sciences, The University of Western Australia, Perth, Australia., Dick IM; National Centre for Asbestos Related Diseases (NCARD). Lv5 QQ Block (M503). QEII Medical Centre, The University of Western Australia, Perth, Australia.; School of Biomedical Sciences, The University of Western Australia, Perth, Australia., Nowak AK; National Centre for Asbestos Related Diseases (NCARD). Lv5 QQ Block (M503). QEII Medical Centre, The University of Western Australia, Perth, Australia.; School of Medicine, The University of Western Australia, Perth, Australia., Robinson BW; National Centre for Asbestos Related Diseases (NCARD). Lv5 QQ Block (M503). QEII Medical Centre, The University of Western Australia, Perth, Australia.; School of Medicine, The University of Western Australia, Perth, Australia., Lake RA; National Centre for Asbestos Related Diseases (NCARD). Lv5 QQ Block (M503). QEII Medical Centre, The University of Western Australia, Perth, Australia.; School of Medicine, The University of Western Australia, Perth, Australia., Fisher SA; National Centre for Asbestos Related Diseases (NCARD). Lv5 QQ Block (M503). QEII Medical Centre, The University of Western Australia, Perth, Australia.; School of Biomedical Sciences, The University of Western Australia, Perth, Australia.
Publikováno v:
Oncoimmunology [Oncoimmunology] 2018 Jul 30; Vol. 7 (10), pp. e1494111. Date of Electronic Publication: 2018 Jul 30 (Print Publication: 2018).
Autor:
Fisher SA; School of Medicine and PharmacologyUniversity of Western Australia, QEII Medical CentreNedlandsWestern AustraliaAustralia; National Research Centre for Asbestos Related DiseasesQEII Medical CentreNedlandsWestern AustraliaAustralia., Aston WJ; School of Medicine and PharmacologyUniversity of Western Australia, QEII Medical CentreNedlandsWestern AustraliaAustralia; National Research Centre for Asbestos Related DiseasesQEII Medical CentreNedlandsWestern AustraliaAustralia., Chee J; School of Medicine and PharmacologyUniversity of Western Australia, QEII Medical CentreNedlandsWestern AustraliaAustralia; National Research Centre for Asbestos Related DiseasesQEII Medical CentreNedlandsWestern AustraliaAustralia., Khong A; School of Medicine and PharmacologyUniversity of Western Australia, QEII Medical CentreNedlandsWestern AustraliaAustralia; National Research Centre for Asbestos Related DiseasesQEII Medical CentreNedlandsWestern AustraliaAustralia., Cleaver AL; School of Medicine and PharmacologyUniversity of Western Australia, QEII Medical CentreNedlandsWestern AustraliaAustralia; National Research Centre for Asbestos Related DiseasesQEII Medical CentreNedlandsWestern AustraliaAustralia., Solin JN; School of Medicine and PharmacologyUniversity of Western Australia, QEII Medical CentreNedlandsWestern AustraliaAustralia; National Research Centre for Asbestos Related DiseasesQEII Medical CentreNedlandsWestern AustraliaAustralia., Ma S; School of Medicine and PharmacologyUniversity of Western Australia, QEII Medical CentreNedlandsWestern AustraliaAustralia; National Research Centre for Asbestos Related DiseasesQEII Medical CentreNedlandsWestern AustraliaAustralia., Lesterhuis WJ; School of Medicine and PharmacologyUniversity of Western Australia, QEII Medical CentreNedlandsWestern AustraliaAustralia; National Research Centre for Asbestos Related DiseasesQEII Medical CentreNedlandsWestern AustraliaAustralia., Dick I; School of Medicine and PharmacologyUniversity of Western Australia, QEII Medical CentreNedlandsWestern AustraliaAustralia; National Research Centre for Asbestos Related DiseasesQEII Medical CentreNedlandsWestern AustraliaAustralia., Holt RA; British Columbia Cancer Agency Vancouver British Columbia Canada., Creaney J; School of Medicine and PharmacologyUniversity of Western Australia, QEII Medical CentreNedlandsWestern AustraliaAustralia; National Research Centre for Asbestos Related DiseasesQEII Medical CentreNedlandsWestern AustraliaAustralia., Boon L; Bioceros Utrecht The Netherlands., Robinson B; School of Medicine and PharmacologyUniversity of Western Australia, QEII Medical CentreNedlandsWestern AustraliaAustralia; National Research Centre for Asbestos Related DiseasesQEII Medical CentreNedlandsWestern AustraliaAustralia., Lake RA; School of Medicine and PharmacologyUniversity of Western Australia, QEII Medical CentreNedlandsWestern AustraliaAustralia; National Research Centre for Asbestos Related DiseasesQEII Medical CentreNedlandsWestern AustraliaAustralia.
Publikováno v:
Immunity, inflammation and disease [Immun Inflamm Dis] 2016 Nov 21; Vol. 5 (1), pp. 16-28. Date of Electronic Publication: 2016 Nov 21 (Print Publication: 2017).